ORCID is part of the wider digital infrastructure needed for researchers to share information on a global scale. ORCID enables transparent and trustworthy connections between researchers, their contributions, and affiliations by providing an identifier for individuals to use with their name as they engage in research, scholarship and innovation activities. The Open Pharma community is … Continue reading Guest post: ORCID adoption in the pharma community
Our new educational resource, an infographic on ORCID, is now available on the Open Pharma website.
We aimed to gain insight into the publishing industry’s perspective on new innovations in the field, as their collaboration will be key to implementing changes.
Featuring the whodunit on the demise of Beall’s list, The Royal Society’s ORCID mandate and how authors and reviewers have responded to PeerJ’s optional open peer review. Who killed Beall's list? via The Chronicle of Higher Education A review of the prime suspects in the demise of Beall’s list, and a discussion on where open … Continue reading Weekly digest: the latest news on topics important to Open Pharma
Based on our experience, we believe that ORCID can make medical publishing faster and more transparent.
Summary report from the Open Pharma workstream meetings in July
With CRediT, ORCID and Publons integrated into Editorial Manager®, we aim for these transparency tools to be easy, standard steps in the publishing process
Since the launch of Open Pharma in January 2017, groups of stakeholders have convened on a monthly basis to explore how to implement positive changes in scientific publishing across four key areas: open access; ORCID, CRediT and Convey; preprints and post-publication peer review; and layered publication platforms. The collated key insights and next steps from … Continue reading Update on Open Pharma workstreams: June 2017
The first Open Pharma workstream meetings took place last week. The collated key insights and next steps can be found below. If you would like to get involved, please refer to our contacts page. Workstream 1: Open access Key insights Next steps Before driving change, we need to define what we mean by open access Define … Continue reading Overview: Open Pharma workstream kick-off meetings
Questions from delegates at ISMPP US 2017 guided poster tour highlight practical issues presenting barriers to uptake of innovative platforms